Abstract Topics

  • Antimicrobials
    • Novel antimicrobial treatments 
    • Resistance 
    • Pharmacology
    • Antibiotic Stewardship
  • Public health and epidemiology (only non SARS-CoV2 content)
    • Population studies and surveillance
    • Modelling studies
  • Vaccines (only non SARS-CoV2 content)
    • Vaccine development (phase 1-2) –  viral
    • Vaccine development (phase 1-2)  – bacterial and all non-viral
    • Vaccine efficacy (phase 3) and effectiveness – viral
    • Vaccine efficacy (phase 3) and effectiveness – bacterial and all non-viral
    • Vaccine safety (post licensure)
    • Vaccine hesitancy
  • Immunology & compromised host
    • Host-pathogen interaction
    • Host response diagnostics and imaging
    • Severe/systemic fungal infections
    • Infections in immunocompromised/immunodeficient patients
  • Global health
    • Zoonosis, vector-borne and emerging infections
    • Tropical/parasite infections & travel medicine
    • Refugees and migrants
  • Infections in early life
    • Congenital and perinatal infections
    • Neonatal sepsis
  • Non-respiratory infections
    • Gastrointestinal infections – Hepatitis
    • Urogenital infections
    • CNS infections
    • Sepsis, systemic and multi-organ infections
    • Skeletal infections
    • Skin Infections
    • STDs
  • Respiratory infections (only non-SARS-CoV2 content)
    • Viral respiratory infections 
    • Bacterial pneumonia
    • ENT infections
  • Mycobacteria and retroviruses
    •  Tuberculosis and other mycobacterial infections
    • HIV/AIDS
  • Digital tools and machine learning
    • Decision support tools 
    • Artificial intelligence in microbiology and radiology
    • Telemedicine
  • Diagnostics and biomarkers
  • Health associated infections, infection prevention and control
  • COVID 19 and MIS-C
  • Microbiome
  • Prolonged/recurrent fever
  • Other
Print Friendly, PDF & Email
Register Now Book Hotel Subscribe